Seat­tle Ge­net­ics/Astel­las win pri­or­i­ty US re­view for armed an­ti­body aimed at blad­der can­cer

Seat­tle Ge­net­ics has se­cured a speedy re­view of its sec­ond armed an­ti­body, cour­tesy of the FDA.

The com­pa­ny’s ‘break­through’ Astel­las-part­nered drug — en­for­tum­ab ve­dotin — has pro­cured …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER